Table 2

Changes in outcome measures from the second baseline measurements at five and 14 weeks of treatment and three weeks after end of treatment, according to treatment group

Week 5 of treatmentWeek 14 of treatmentThree weeks after end of treatment
PSM (n = 31)Placebo (n = 31)Δ (95% CI) p valuePSM (n = 31)Placebo (n = 31)Δ (95% CI) p valuePSM (n = 31)Placebo (n = 31)Δ (95% CI) p value
Change is calculated as the scores at or after intervention minus the scores at baseline and is presented as mean (SD). The difference in change between groups (Δ) is calculated from the change in the pyridostigmine group minus the change in the placebo group and is presented as mean difference (95% confidence interval) and the p value of the t test.
*n = 9; †n = 12; ‡n = 19; §n = 20; ¶n = 23; **n = 26; ††n = 28; ‡‡n = 29; §§n = 30.
CI, confidence interval; FSS, fatigue severity scale; Max, maximum; MF, median frequency; NHPE, Nottingham health profile, category “energy”; NMT, neuromuscular transmission; PSM, pyridostigmine.
NHPE (range 0–100)−10.8 (35.9)−10.8 (26.4)0.0 (16.0 to −16.0)−18.3 (36.4)−17.2 (33.2)−1.1 (−18.8 to 16.6)−6.5 (37.9)−8.6 (25.8)2.2 (−14.3 to 18.6)
p = 0.11p = 0.031.00p = 0.01p = 0.010.90p = 0.35p = 0.070.80
FSS (range 1–7)−0.2 (0.7)−0.4 (0.5)0.1 (−0.2 to 0.4)−0.6 (0.9)−0.4 (0.9)−0.2 (−0.6 to 0.3)−0.5 (1.0)−0.4 (0.6)−0.1 (−0.6 to 0.3)
p = 0.07p<0.010.44p<0.01p = 0.010.48p<0.01p<0.010.48
Subjective benefit of treatment
Question 10.5 (0.7)0.5 (0.8)−0.1 (−0.5 to 0.3)0.5 (0.9)0.5 (0.9)−0.1 (−0.5 to 0.4)
p<0.01p<0.0010.61p = 0.01p<0.010.78
Question 20.4 (0.8)0.4 (0.9)−0.1 (−0.5 to 0.4)0.5 (0.9)0.5 (0.9)−0.1 (−0.5 to 0.4)
p = 0.01p = 0.020.76p = 0.01p<0.010.78
Two minute walking distance (m)8.6 (9.9)§§5.8 (5.9)2.8 (−1.4 to 7.0)10.2 (9.4)3.0 (8.8)7.2 (2.6 to 11.9)12.7 (9.3)6.0 (9.6)6.8 (2.0 to 11.6)
p<0.001p<0.0010.18p<0.001p = 0.070.003p<0.001p<0.010.01
Max walking performance, 75 m (s)−1.1 (3.5)0.5 (5.8)§§−1.5 (−4.0 to 0.9)−1.6 (4.4)0.1 (4.0)††−1.7 (−3.9 to 0.5)−1.9 (4.1)‡‡0.6 (4.4)§§−2.6 (−4.8 to −0.3)
p = 0.09p = 0.760.21p = 0.06p = 0.890.13p = 0.02p = 0.620.03
Duration of walking (% of total time)1.5 (1.3)†1.0 (1.7) *0.5 (−0.8 to 1.9)
p<0.01p = 0.120.42
Quadriceps strength (Nm)6.7 (13.7)5.0 (13.9)1.7 (−5.3 to 8.7)12.7 (21.4)6.0 (13.4)6.7 (−2.4 to 15.7)5.1 (19.0)3.7 (12.1)1.5 (−6.6 to 9.5)
p = 0.01p = 0.060.63p<0.01p = 0.020.15p = 0.14p = 0.100.72
Max voluntary activation (range 0–100)6.5 (14.3)¶−4.7 (11.3)‡11.1 (3.0 to 19.3)7.7 (14.2)¶1.1 (14.2)‡6.6 (−2.2 to 15.5)5.8 (13.2)**−3.3 (12.7)§9.1 (1.3 to 16.8)
p = 0.04p = 0.090.01p = 0.02p = 0.740.14p = 0.03p = 0.260.02
Muscle fatiguability (MF0–5s–MF25–30s)0.1 (2.9) **−0.0 (3.5)††0.2 (−1.6 to 1.9)0.9 (3.4)**0.2 (3.3)**0.7 (−1.1 to 2.6)0.9 (3.1)**0.4 (4.0)††0.4 (−1.5 to 2.4)
p = 0.82p = 0.960.85p = 0.18p = 0.800.43p = 0.17p = 0.580.66
NMT, jitter (μs)−5.6 (16.0)−2.8 (21.1)††−2.8 (−12.5 to 6.9)
p = 0.06p = 0.490.57